Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cetirizine + fluticasone** is a combination of two active pharmaceutical ingredients commonly used together for the symptomatic treatment of allergic rhinitis and related allergic symptoms. Cetirizine is a second-generation antihistamine (selective Histamine H1 receptor antagonist) primarily used for reducing sneezing, pruritus, and rhinorrhea by blocking the action of histamine at the H1 receptor site. Fluticasone is a synthetic corticosteroid with potent anti-inflammatory activity that reduces nasal inflammation and congestion via local effects on nasal mucosa. The combination leverages the rapid anti-symptom effects of cetirizine with the longer-term anti-inflammatory effects of fluticasone, often producing synergistic relief of both nasal and extra-nasal symptoms of allergic rhinitis where monotherapy is insufficient. Both molecules are well-tolerated and frequently used together when mono-therapy is inadequate for moderate-to-severe allergic disease[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetirizine + fluticasone.